A survival benefit was replicated in a similar ePROM RCT, conducted by Denis et al., in a cohort of patients undergoing treatment for lung cancer in France using the ‘e-FAP’ (e-Follow-Up Application) (median survival difference 7.6 months; 2 year follow-up; hazard ratio, 0.59 95% CI, 0.37 to 0.96) [13, 14]. This evidence concerns the gene FAP and lung carcinoma.